Chitinase Signature in the Plasticity of Neurodegenerative Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Apr 13

PMID 37047273

Authors

Cristina Russo

Maria Stella Valle

Antonino Casabona

Lucia Malaguarnera

Affiliations

Soon will be listed here.

Abstract

Several reports have pointed out that Chitinases are expressed and secreted by various cell types of central nervous system (CNS), including activated microglia and astrocytes. These cells play a key role in neuroinflammation and in the pathogenesis of many neurodegenerative disorders. Increased levels of Chitinases, in particular Chitotriosidase (CHIT-1) and chitinase-3-like protein 1 (CHI3L1), have been found increased in several neurodegenerative disorders. Although having important biological roles in inflammation, to date, the molecular mechanisms of Chitinase involvement in the pathogenesis of neurodegenerative disorders is not well-elucidated. Several studies showed that some Chitinases could be assumed as markers for diagnosis, prognosis, activity, and severity of a disease and therefore can be helpful in the choice of treatment. However, some studies showed controversial results. This review will discuss the potential of Chitinases in the pathogenesis of some neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis, to understand their role as distinctive biomarkers of neuronal cell activity during neuroinflammatory processes. Knowledge of the role of Chitinases in neuronal cell activation could allow for the development of new methodologies for downregulating neuroinflammation and consequently for diminishing negative neurological disease outcomes.

Citing Articles

Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications.

Mwale P, Hsieh C, Yen T, Jan J, Taliyan R, Yang C Mol Neurodegener. 2025; 20(1):7.

PMID: 39827337 PMC: 11742494. DOI: 10.1186/s13024-025-00801-8.

From Fundamentals to Innovation in Alzheimer's Disease: Molecular Findings and Revolutionary Therapies.

Sighencea M, Popescu R, Trifu S Int J Mol Sci. 2024; 25(22).

PMID: 39596378 PMC: 11594972. DOI: 10.3390/ijms252212311.

New insights into the role of the CHI3L2 protein in invasive ductal breast carcinoma.

Rusak A, Katnik E, Gornicki T, Schmuttermaier C, Kujawa K, Piotrowska A Sci Rep. 2024; 14(1):28529.

PMID: 39557919 PMC: 11574116. DOI: 10.1038/s41598-024-77930-5.

Computational analysis of peripheral blood RNA sequencing data unravels disrupted immune patterns in Alzheimer's disease.

Anatolou D, Krokidis M AIMS Neurosci. 2024; 11(2):103-117.

PMID: 38988883 PMC: 11230858. DOI: 10.3934/Neuroscience.2024007.

CHIT1 at diagnosis predicts faster disability progression and reflects early microglial activation in multiple sclerosis.

Belien J, Swinnen S, Dhondt R, Verdu de Juan L, Dedoncker N, Matthys P Nat Commun. 2024; 15(1):5013.

PMID: 38866782 PMC: 11169395. DOI: 10.1038/s41467-024-49312-y.

References

Orihuela R, McPherson C, Harry G . Microglial M1/M2 polarization and metabolic states. Br J Pharmacol. 2015; 173(4):649-65. PMC: 4742299. DOI: 10.1111/bph.13139. View

Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmestrom C . Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem. 2016; 141(2):296-304. DOI: 10.1111/jnc.13881. View

Al-Chalabi A, Hardiman O, Kiernan M, Chio A, Rix-Brooks B, van den Berg L . Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016; 15(11):1182-94. DOI: 10.1016/S1474-4422(16)30199-5. View

Gitler A, Dhillon P, Shorter J . Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech. 2017; 10(5):499-502. PMC: 5451177. DOI: 10.1242/dmm.030205. View

Dugger B, Dickson D . Pathology of Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2017; 9(7). PMC: 5495060. DOI: 10.1101/cshperspect.a028035. View

Tang Y, Le W . Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. Mol Neurobiol. 2015; 53(2):1181-1194. DOI: 10.1007/s12035-014-9070-5. View

Rehli M, Krause S, Andreesen R . Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997; 43(2):221-5. DOI: 10.1006/geno.1997.4778. View

Bartl M, Dakna M, Galasko D, Hutten S, Foroud T, Quan M . Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease. PLoS One. 2021; 16(10):e0257372. PMC: 8496858. DOI: 10.1371/journal.pone.0257372. View

Cashion J, Young K, Sutherland B . How does neurovascular unit dysfunction contribute to multiple sclerosis?. Neurobiol Dis. 2023; 178:106028. DOI: 10.1016/j.nbd.2023.106028. View

10.

Al-Chalabi A, Hardiman O . The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013; 9(11):617-28. DOI: 10.1038/nrneurol.2013.203. View

11.

Johansen J . Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006; 53(2):172-209. View

12.

Huang C, Zhou H, Tong J, Chen H, Liu Y, Wang D . FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet. 2011; 7(3):e1002011. PMC: 3048370. DOI: 10.1371/journal.pgen.1002011. View

13.

Wattmo C, Blennow K, Hansson O . Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease. BMC Neurol. 2020; 20(1):10. PMC: 6951013. DOI: 10.1186/s12883-019-1591-0. View

14.

Wennstrom M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O . The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. PLoS One. 2015; 10(8):e0135458. PMC: 4536228. DOI: 10.1371/journal.pone.0135458. View

15.

Bi F, Huang C, Tong J, Qiu G, Huang B, Wu Q . Reactive astrocytes secrete lcn2 to promote neuron death. Proc Natl Acad Sci U S A. 2013; 110(10):4069-74. PMC: 3593910. DOI: 10.1073/pnas.1218497110. View

16.

Dichev V, Kazakova M, Sarafian V . YKL-40 and neuron-specific enolase in neurodegeneration and neuroinflammation. Rev Neurosci. 2020; 31(5):539-553. DOI: 10.1515/revneuro-2019-0100. View

17.

Lu S, Guo Y, Liang P, Zhang S, Yin S, Yin Y . Suppression of astrocytic autophagy by αB-crystallin contributes to α-synuclein inclusion formation. Transl Neurodegener. 2019; 8:3. PMC: 6337871. DOI: 10.1186/s40035-018-0143-7. View

18.

Rosen C, Andersson C, Andreasson U, Molinuevo J, Bjerke M, Rami L . Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. Dement Geriatr Cogn Dis Extra. 2014; 4(2):297-304. PMC: 4164083. DOI: 10.1159/000362164. View

19.

Farina C, Aloisi F, Meinl E . Astrocytes are active players in cerebral innate immunity. Trends Immunol. 2007; 28(3):138-45. DOI: 10.1016/j.it.2007.01.005. View

20.

Wills-Karp M, Nathan A, Page K, Karp C . New insights into innate immune mechanisms underlying allergenicity. Mucosal Immunol. 2009; 3(2):104-10. PMC: 2821449. DOI: 10.1038/mi.2009.138. View